Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Association of sBCMA with measures of disease burden & response to linvoseltamab in R/R myeloma

Anita Boyapati • 28 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Linvoseltamab

Anita Boyapati, PhD, Regeneron Pharmaceuticals, Tarrytown, NY, discusses the results of a study which showed that soluble BCMA (sBCMA) concentration is modestly correlated with measures of disease burden in patients with relapsed/refractory multiple myeloma (R/R MM) treated with linvoseltamab. The study also showed that patients with very high baseline sBCMA demonstrated high overall response rates (ORR) to linvoseltamab. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Regeneron employee and shareholder

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals